Abel Hall LLC
FATE icon

Abel Hall LLC’s Fate Therapeutics FATE Stock Holding History

Abel Hall LLC’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$85K Sell
35,850
-22
-0.1% -$57 0.02% 799
2026
Q2 		$96.9K Sell
35,872
-876
-2% -$1.62K 0.02% 838
2026
Q1 		$44.1K Buy
+36,748
New +$44.7K 0.01% 754

Other funds holding FATE

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $142M AUM 113.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Parcion Private Wealth
Parcion Private Wealth Bellevue, Washington $1.85B AUM 22.28% 1-Year Est. Return
Northern Lights Advisors
Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return
Owl Creek Wealth Partners
Owl Creek Wealth Partners Denver, Colorado $355M AUM
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Abel Hall LLC's FATE Position: Q3 2026 in Review

Abel Hall LLC reduced its Fate Therapeutics (FATE) stake by 0.06% in Q3 2026, selling an estimated $57 and leaving 35,850 shares worth $85K. The position accounts for 0.02% of the portfolio, ranked #799.

Abel Hall LLC first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $96.9K in Q2 2026. 20 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Abel Hall LLC held 35,850 shares of Fate Therapeutics worth $85K as of Q3 2026.
  • Abel Hall LLC sold 22 Fate Therapeutics shares in Q3 2026, an estimated $57.
  • Fate Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q3 2026, its #799 holding.
  • Abel Hall LLC first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Abel Hall LLC's Fate Therapeutics position peaked at $96.9K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.